Immorta Bio
CompanyUnited States
Immorta Bio develops one asset, preclinical (SenoMune-0257 in aging). Mostly peptide acting on cellular senescence; based in the United States.
- 1
- Asset
- Furthest stage
- Preclinical
- 0
- Trials
- 1
- Signal
Pipeline
1Stimulates cytotoxic T cells to selectively eliminate senescent cells while sparing healthy cells.
Preclinical, Peptide, Cellular senescence, aging
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals1
- Similar companies6
Papers
Reduction of solid tumors by senescent cell immunization
Journal of translational medicine, 29 Nov 2025
Reversing coma by senolytics and stem cells: the future is now
Journal of translational medicine, 8 Oct 2025